![]() Actinium Pharmaceuticals Actinium Pharmaceuticals is a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers. | ![]() Juno Therapeutics Juno Therapeutics is a clinical-stage company, which develops immunotherapies for the treatment of cancer. | ![]() Aceragen Aceragen (formerly known as Idera Pharmaceuticals) is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates. | |
Founding Date | Founding Date 2000 | Founding Date 2013 | Founding Date 1989 |
Type | Type Public | Type Subsidiary | Type Public |
Tags | |||
Locations | Locations New York, US HQ | Locations Seattle, US HQ Göttingen, DE Göttingen, DE München, DE München, DE Bothell, US Brisbane, US | Locations Durham, US HQ |
Employees | Employees 2517% decrease | Employees 1091% decrease | Employees 3642% decrease |
Valuation ($) | Valuation ($) 58.6 m | Valuation ($) N/A | Valuation ($) 3.2 m |
Financial | |||
Revenue (est.) | Revenue (est.) $90k (FY, 2025) | Revenue (est.) $111.9m (FY, 2017) | Revenue (est.) $4.9m (FY, 2022) |
Net income | Net income N/A | Net income ($437.1m) (FY, 2017) | Net income ($23.4m) (FY, 2022) |
Funding | |||
Total funding raised | Total funding raised $ 7m | Total funding raised $ 310m | Total funding raised $ 13.8m |

Juno Therapeutics is a clinical-stage company, which develops immunotherapies for the treatment of cancer.
View company
Aceragen (formerly known as Idera Pharmaceuticals) is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
View company